Reply: The value of cytogenetic analysis of the product of conception before preimplantation genetic screening Sir, Thank you for your letter regarding our recent publication, Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss (Murugappan et al., 2016) . We agree, as you have stated, that aneuploidy plays a significant role in clinical miscarriage as well as in recurrent pregnancy loss. Miscarriage in RPL patients, however, may have multiple other contributing factors, and this has been discussed in the literature. The authors of the letter highlight a study by Ogasawara in 2000 demonstrating that abnormal karyotypes in products of conception (POCs) become less frequent as the number of miscarriages increases (Ogasawara et al., 2000) . Marquard et al. has demonstrated that the rate of aneuploidy in POCs from RPL patients is not significantly higher than aneuploidy rates seen in sporadic miscarriages, suggesting that an additional factor may have a role in contributing to clinical miscarriage in RPL patients (Manquard et al., 2010) . In a 2012 study by Ogasawara, the cumulative live birth rate in women with prior aneuploidy in POC was 71.9% compared with a 44.7% live birth rate in women with prior euploid losses (Sugiura-Ogasawara et al., 2012) . This was a good prognostic sign for both expectant management and possibly for IVF-PGS. In patient with two consecutive miscarriages with the first loss being aneuploid, 32 of 42 or 76% had a second aneuploid loss, suggesting that the karyotype results of one miscarriage do not always predict the results of the second miscarriage or predict if the patient is at higher risk of aneuploid conception.
The authors of the letter suggest using POC karyotyping to identify RPL patients with a clear history of chromosome aneuploidy and offer PGS to this subset of the RPL population. We acknowledge that a limitation of the study was that karyotype information on POC from previous miscarriages was not available for the majority of RPL patients in the study, and we were therefore unable to report this. Furthermore, due to the retrospective nature of the study design, the patients were included in the PGS cohort if they expressed a desire to pursue treatment. While karyotypes should ideally be obtained after every clinical miscarriage, there are many barriers to performing this in clinical settings so providers often need to counsel patients without this information. Within an idiopathic RPL population, we agree that some patients may benefit more than others from PGS over expectant management. Our study, however, was not designed to identify the subset of RPL patients for whom PGS may provide the greatest incremental benefit over expectant management. Our goal was to capture the actual use of PGS, not perfect use of the technology. While many studies of PGS report live birth rates per euploid embryo transferred, we wished to convey that not every RPL patient who desires to perform PGS arrives to the point of transferring a euploid embryo. We did report that older patients with DOR are at higher risk of treatment failure with PGS. In our current management of RPL patients, PGS may very well be offered to patients in whom it is unnecessary. Our hope was to convey that expectant management is an alternative and equally successful treatment strategy.
As we continue to scrutinize our utilization of PGS in the RPL population, we would be very interested to see RPL patients riskstratified and PGS being offered to those patients with a proven history of aneuploidy to determine if these patients in fact receive the greatest benefit from this technology. Comparing IVF and PGS to expectant management is challenging, as there are many factors that influence success rates of each option. We hope that prospective studies include an intent to treat as well as expectant management arm, as patients who are at risk of not reaching euploid embryo transfer with IVF and PGS may have a higher live birth rate with expectant management. In addition, future studies should include data about POC karyotype, maternal age, ovarian reserve and number of miscarriages to help identify groups that are most likely to benefit or be harmed by the use of PGS. Should we also work on an international informed consent for endometriosis surgery?
Sir, We read the consensus opinion on the recording of deep endometriosis findings at surgery with great interest. The consensus established by the group of experts will be, without a doubt, extremely useful for comparing surgical techniques and practices. It should have a direct impact on the quality of studies, and should help, as mentioned in the paper, to turn opinion into science. However, I have some concerns on the consensus regarding information provided to the patient.
We believed that, as in many fields in surgery, there should be an internationally agreed informed consent form. This form when agreed upon should be translated into all relevant languages, and provided to international societies, and individual physicians. Consequently, all patients will receive the same information, before surgery about the complications, alternatives, chance of success, risk of recurrence and potential fertility outcomes. An agreed and established international consent form will also be helpful if there is litigation after surgery with a high risk of complications.
Additionally, an identical international informed consent form may improve pre-operative evaluation. Indeed, before signing this form, physicians will have to check if appropriate pre-operative evaluation has been carried out for each potential lesion. Pre-operative evaluation is a key step leading to the success of endometriosis surgery. This informed consent form could be a useful tool to evaluate the efficacy of the preoperative evaluation and subsequent surgical outcome. Moreover, it should ensure that patients receive accurate and agreed information regarding the surgical procedure.
